Tag Archives: Alprolix

November, 2017

• 27 November

  FDA Updates Label for Alprolix, Adding Long-Term Safety and Efficacy Data

  

  WALTHAM, Mass.–(BUSINESS WIRE)–Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved updated labeling for ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein], the leading extended half-life therapy for the …

  Share

  • Facebook
  • Twitter
  • LinkedIn

March, 2015

• 2 March

  Biogen and Sobi’s Hemophilia B Drug Succeeds in Phase III Trial in Children

  

  Biogen Idec and Swedish Orphan Biovitrum AB (Sobi) recently announced positive results from its late-stage hemophilia B study. The companies announced top-line results of the Kids B-LONG Phase III clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in children under …

  Share

  • Facebook
  • Twitter
  • LinkedIn